ECCMID
The partnership, announced last week just before ECCMID kicked off, is the first major foray for both companies into the sequencing-based infectious disease diagnostics market.
The firm's planned launches include a respiratory virus panel, a gastrointestinal panel, and a fingerstick tuberculosis test, it revelaed this week at ECCMID.
Multicenter Study Finds BioFire Joint Infection Panel Shows High Accuracy Despite Limitations
Premium
The assay received de novo authorization from the US Food and Drug Administration and CE-IVD marking last year.
The company will launch 37 CE-IVD-marked assays this year, mostly for infectious diseases, for use on the QuantStudio 5 Dx and eventually QuantStudio 7 Pro Dx platforms.
Powered by MGI Tech, 'Million Microbiomes' Project Back on Track After COVID Slowdown
Researchers involved with the Million Microbiomes from Humans Project provided an update on the effort during an MGI-sponsored symposium at ECCMID.